Melanoma Market to Witness Promising Growth, Predicts DelveInsight | Key Companies To Watch - IO Biotech, Merck, Eisai, Regeneron, Genentech, Seagen, Amgen, Astellas, Galectin, MedImmune, Aivita, Linnaeus, Checkmate, OnKure

The dynamics of the melanoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, and incremental healthcare spending across the world along with the launch of several emerging therapies during the forecast period of 2023–2032.

LAS VEGAS, June 12, 2023 /PRNewswire/ -- DelveInsight's Melanoma Market Insights report includes a comprehensive understanding of current treatment practices including the major advancements in immunomodulatory and targeted therapies, melanoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Melanoma Market Report

• As per DelveInsight analysis, the melanoma market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• According to the SEER estimates, 106,110 new cases of melanoma were observed in 2021. More than half of the new cases occur in patients with 60+ years of age, and it is expected to rise by 2032.
• Leading melanoma companies such as IO Biotech, Merck Sharp & Dohme, Eisai, Regeneron Pharmaceuticals, Iovance Biotherapeutics, Highlight Therapeutics, Linnaeus Therapeutics, Spring Bank Pharmaceuticals, Taiga Biotechnologies, Inc., Aivita Biomedical, Inc., Genentech, Inc., Dana-Farber Cancer Institute, BioMed Valley Discoveries, Inc, Amgen, Checkmate Pharmaceuticals, Astellas Pharma Inc, Galectin Therapeutics Inc., Eucure (Beijing) Biopharma Co., Ltd, Mologen AG, Ultimovacs ASA, Seagen Inc., MedImmune LLC, OnKure, Inc., Syntrix Biosystems, Inc., Anaveon AG, iOx Therapeutics, Portage Biotech, ModernaTX, Inc., Nektar Therapeutics, BioNTech SE, Sapience Therapeutics, HUYABIO International, LLC., Provectus Biopharmaceuticals, Inc., Cantargia AB, Turnstone Biologics, Corp., Aura Biosciences, F-star Therapeutics, Inc., Day One Biopharmaceuticals, Inc., Kinnate Biopharma, Xencor, Inc., HiFiBiO Therapeutics, and others are developing novel melanoma drugs that can be available in the melanoma market in the coming years.
• Some key therapies for melanoma treatment include IO102-IO103, LENVIMA (lenvatinib), Vidutolimod (CMP-001), Lifileucel (LN-144), BO-112 with Pembrolizumab, LNS8801, SB11285, TBX-3400, CA-4948, AV-MEL-1, Atezolizumab, BVD-523, T-Vec, CMP-001, Pudexacianinium chloride, GR-MD-02, YH003, MGN1703, UV1, SGN-BB228, MEDI0562, OKI-179 + binimetinib, SX-682, ANV419,  rSIFN-co, IMM60, Talimogene laherparepvec, mRNA-4157, NKTR-214, RO7198457, ST316, BNT111, HBI-8000 in combination with nivolumab, PV-10, CAN04, TBio-4101, AU-011, SB 11285, DAY101, KIN-2787, XmAb®808, HFB200603, and others.
• In May 2023, the FDA has given the tumor-infiltrating lymphocyte (TIL) medication lifileucel (LN-144) a priority review for the treatment of patients with metastatic melanoma who progressed on or after prior anti-PD-1/PD-L1 therapy and targeted therapy.
• In May 2023, Regeneron Pharmaceuticals, Inc. announced promising findings from three independent cohorts assessing an experimental combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo (cemiplimab) in individuals with advanced melanoma were presented.
• In April 2023, IDEAYA Biosciences, Inc., a precision medicine oncology business dedicated to the discovery and development of targeted therapies, released additional interim data from its Phase 2 clinical trial investigating the combination of darovasertib and crizotinib in patients with metastatic uveal melanoma (MUM).
• In March 2023, the FDA approved Bristol Myers Squibb's supplementary Biologics Licence Application for nivolumab (Opdivo) as an adjuvant treatment for individuals with fully resected stage 2B or 2C melanoma. 
• In August 2022, Iovance initiated a rolling Biologics License Application (BLA) submission to the FDA for lifileucel in patients with advanced (unresectable or metastatic) melanoma who progressed on or after prior anti-PD-1/L1 therapy, and if BRAF mutation-positive, also prior BRAF or BRAF/MEK inhibitor therapy. 

Discover which therapies are expected to grab the major melanoma market share @ Melanoma Market Report

Melanoma Overview

Melanoma is a type of skin cancer that develops from melanin cells in the skin's upper layer or from similar cells present in moles. This type of skin cancer can send roots deep into the skin's layers, and some of these microscopic roots can spread (metastasize), generating new tumor growths in crucial organs. The actual cause of malignant melanoma is unknown. Excessive sun exposure, particularly before puberty, and living in places where the sun is stronger increase the chance of acquiring skin cancer. A faulty gene known as CDK4 has been identified and may be linked to an increased risk of familial malignant melanoma.

Melanoma Diagnosis

Early identification and recognition of skin cancer are critical. Recognizing the early warning symptoms of melanoma and performing regular self-examinations of the skin can help detect melanoma when it is more treatable. Doctors employ a variety of tests to detect or diagnose cancer. A physical exam and a biopsy are included in the initial evaluation. Depending on the results of the assessment, imaging tests are performed to determine if cancer has spread to another part of the body from where it began, such as ultrasound, computed tomography (CT or CAT) scan, magnetic resonance imaging (MRI), and positron emission tomography (PET) or PET-CT scan.

Melanoma Epidemiology Segmentation

The melanoma epidemiology section provides insights into the historical and current melanoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and patient prevalent forecasts and models by exploring numerous studies and views of key opinion leaders.

The melanoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Melanoma Incident Cases 
• Melanoma Type-specific Cases
• Melanoma Stage-specific Incident Cases
• Melanoma Mutation-specific  (BRAF, MEK) Incident Cases
• Melanoma Age-specific Incident Cases
• Total Melanoma Treated Cases

Melanoma Treatment Market 

Melanoma treatment focuses on extending survival, removing cancer, decreasing or preventing the growth of known metastases, and treating symptomatic or dangerous disease sites to provide comfort. Melanoma treatment options include immunotherapy, targeted therapy, intralesional therapy, chemotherapy, and radiation therapy. Surgery, on the other hand, is considered an option in some cases.

Yervoy (ipilimumab), which was approved by the FDA in 2011 for patients with stage IV melanoma, was the first checkpoint blockade medication that helped decrease many tumors significantly and lengthen patients' lives. Ipilimumab inhibits CTLA-4, a protein on T cells that acts as a "brake" to control immune system activation. By inhibiting CTLA-4, T lymphocytes are able to attack and kill tumors. Ipilimumab inhibits CTLA-4, a protein on T cells that acts as a "brake" to control immune system activation. By inhibiting CTLA-4, T lymphocytes are able to attack and kill tumors.

While there are more melanoma treatment options available now than ever before, there are even more new techniques being investigated. Researchers are hard at work optimizing therapy combinations and tactics to improve outcomes, building on today's significant forward momentum in understanding and treating melanoma. Advanced melanoma may one day be turned from a fatal disease to a chronic, treatable, and possibly curable condition.

To know more about melanoma treatment, visit @ Melanoma Treatment Drugs 

Key Melanoma Therapies and Companies

• IO102-IO103: IO Biotech
• LENVIMA (lenvatinib): Merck Sharp & Dohme/Eisai
• Vidutolimod (CMP-001): Regeneron Pharmaceuticals
• Lifileucel (LN-144): Iovance Biotherapeutics
• BO-112 with Pembrolizumab: Highlight Therapeutics
• LNS8801: Linnaeus Therapeutics
• SB11285: Spring Bank Pharmaceuticals
• TBX-3400: Taiga Biotechnologies, Inc.
•  CA-4948: Merck Sharp & Dohme LLC
• AV-MEL-1: Aivita Biomedical, Inc.
• Atezolizumab: Genentech, Inc.
• BVD-523: Dana-Farber Cancer Institute/BioMed Valley Discoveries, Inc
• T-Vec: Amgen
• CMP-001: Checkmate Pharmaceuticals
• Pudexacianinium chloride: Astellas Pharma Inc
• GR-MD-02: Galectin Therapeutics Inc.
• YH003: Eucure (Beijing) Biopharma Co., Ltd
• MGN1703: Mologen AG
• UV1: Ultimovacs ASA
• SGN-BB228: Seagen Inc.
• MEDI0562: MedImmune LLC
• OKI-179 + binimetinib: OnKure, Inc.
• SX-682: Syntrix Biosystems, Inc.
• ANV419: Anaveon AG

Learn more about the FDA-approved drugs for melanoma @ Drugs for Melanoma Treatment 

Melanoma Market Dynamics

The dynamics of the melanoma market are expected to change in the coming years. Drug combination therapy may result in more effective disease control. The efficacy of available medication classes, either as monotherapy or in combination, is propelling melanoma market expansion. Moreover, the introduction of innovative medications for neo-adjuvant therapy and the class of new therapeutic drugs to treat melanoma and the market will provide melanoma sufferers hope as a therapeutic option and may have a significant positive influence on the melanoma market.

Furthermore, a better and more precise understanding of melanoma's etiology is likely to dramatically improve treatment regimens and the development of innovative therapies. As a result, various companies have begun to concentrate on the creation of novel therapeutic solutions. The melanoma market is predicted to increase favorably in the next years as a result of currently prescribed drugs as well as the debut of different emerging remedies.

However, several factors are impeding the growth of the melanoma market. Patients are frequently misdiagnosed or have a delayed diagnosis of melanoma, highlighting the lack of robust diagnostic procedures. Melanoma is connected with a number of comorbidities and risk factors, including skin necrosis, discomfort on the skin sore, and lymphoedema, a condition in which the patient's lymph nodes rupture and fluid accumulates in the limbs. Moreover, the melanoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. 

Scope of the Melanoma Market Report

• Melanoma  Therapeutic Assessment: Melanoma current marketed and emerging therapies
• Melanoma Market Dynamics: Attribute Analysis of Emerging Melanoma Drugs
• Melanoma  Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's Views, Analyst's Views, Melanoma Market Access and Reimbursement

Discover more about melanoma drugs in development @ Melanoma Clinical Trials

Table of Contents

Related Reports

Melanoma Pipeline

Melanoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key melanoma companies, including BioMed Valley Discoveries, Inc, Amgen, Checkmate Pharmaceuticals, Astellas Pharma Inc, Galectin Therapeutics Inc., Eucure (Beijing) Biopharma Co., Ltd, Mologen AG, Ultimovacs ASA, Seagen Inc., MedImmune LLC, OnKure, Inc., among others.

Metastatic Melanoma Market

Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic melanoma companies including Neon Therapeutics, BioNTech, Bristol-Myers Squibb, among others.

Refractory Metastatic Melanoma Pipeline

Refractory Metastatic Melanoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key refractory metastatic melanoma companies, including Idera Pharmaceuticals, BioNTech, Bristol-Myers Squibb, among others.

Refractory Metastatic Melanoma Market

Refractory Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory metastatic melanoma companies including Idera Pharmaceuticals, BioNTech, Bristol-Myers Squibb, among others.

For more insights into the melanoma market, visit: Healthcare Blogs

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Stay ahead in business and understand the best-in-class strategies and latest trends shaping the healthcare domain. Get in touch with our experts @ Healthcare Competitive Intelligence Services

Contact Us 
Shruti Thakur  
info@delveinsight.com
+1(919)321-6187  
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg